US Stock MarketDetailed Quotes

BTAI BioXcel Therapeutics

Watchlist
  • 0.341
  • +0.026+8.12%
Close Dec 20 16:00 ET
  • 0.342
  • +0.001+0.26%
Post 20:01 ET
16.49MMarket Cap-0.17P/E (TTM)

BioXcel Therapeutics Key Stats

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
56.53%-16.34M
39.34%-23.17M
66.18%-17.71M
-14.53%-155.01M
30.48%-26.86M
-20.52%-37.58M
-15.42%-38.21M
-61.52%-52.35M
-64.74%-135.34M
-93.85%-38.64M
Net income from continuing operations
72.96%-13.65M
84.49%-8.3M
49.26%-26.79M
-8.02%-179.05M
59.39%-22.26M
-20.76%-50.49M
-42.06%-53.52M
-67.76%-52.8M
-55.01%-165.76M
-109.79%-54.81M
Operating gains losses
-481,900.00%-4.82M
-2,104.40%-12.04M
-112.99%-30K
-206.08%-436K
-125.74%-122K
--1K
---546K
--231K
793.48%411K
--474K
Depreciation and amortization
-2.53%77K
-4.94%77K
-2.50%78K
-2.75%318K
-3.70%78K
-7.06%79K
-3.57%81K
3.90%80K
10.10%327K
6.58%81K
Other non cash items
75.49%1.51M
73.83%1.45M
66.54%1.33M
82.30%3.53M
4.11%1.04M
38.87%861K
--833K
--801K
--1.94M
--997K
Change In working capital
-116.65%-1.32M
-161.48%-5.42M
176.99%4.27M
-80.60%2.02M
-191.36%-9.2M
44.60%7.95M
2,855.31%8.82M
-14.52%-5.55M
108.90%10.4M
159.47%10.07M
-Change in receivables
366.12%809K
-193.24%-434K
-777.14%-307K
171.37%177K
367.74%664K
---304K
---148K
---35K
---248K
---248K
-Change in inventory
1,341.94%1.16M
-992.59%-241K
-1,457.58%-448K
99.70%-6K
104.68%27K
-615.38%-93K
103.79%27K
104.84%33K
---1.99M
---577K
-Change in prepaid assets
-164.82%-1.46M
-131.03%-459K
144.92%901K
173.96%2.89M
13.12%1.16M
5.29%2.25M
141.17%1.48M
42.36%-2.01M
-3,891.26%-3.91M
-44.14%1.03M
-Change in payables and accrued expense
-128.18%-1.74M
-155.72%-4.2M
221.55%4.21M
-104.29%-722K
-208.18%-10.97M
82.88%6.17M
88.87%7.54M
-411.98%-3.46M
247.09%16.83M
396.48%10.14M
-Change in other current liabilities
-8.64%-88K
-10.13%-87K
-7.79%-83K
-8.87%-319K
-9.33%-82K
-9.46%-81K
-8.22%-79K
-8.45%-77K
-23.63%-293K
-8.70%-75K
Cash from discontinued investing activities
Operating cash flow
56.53%-16.34M
39.34%-23.17M
66.18%-17.71M
-14.53%-155.01M
30.48%-26.86M
-20.52%-37.58M
-15.42%-38.21M
-61.52%-52.35M
-64.74%-135.34M
-93.85%-38.64M
Investing cash flow
Cash flow from continuing investing activities
0
85.61%-20K
0
0
68.76%-139K
0
Net PPE purchase and sale
--0
----
----
85.61%-20K
--0
--0
----
----
68.76%-139K
--0
Cash from discontinued investing activities
Investing cash flow
--0
--0
--0
85.61%-20K
--0
--0
-5.26%-20K
--0
68.76%-139K
--0
Financing cash flow
Cash flow from continuing financing activities
454K
2,021.60%5.3M
10.26%26.63M
-72.44%26.52M
4,146.00%2.12M
0
-99.62%250K
24.15M
-6.06%96.24M
50K
Net issuance payments of debt
----
----
----
--0
----
----
----
----
--98.6M
--0
Net common stock issuance
--468K
--5.48M
8.46%26.74M
--27.03M
--2.38M
--0
--0
--24.66M
--0
--0
Proceeds from stock option exercised by employees
--0
--0
--0
79.51%508K
--0
--0
35.14%250K
--258K
-80.54%283K
--50K
Net other financing activities
---14K
---172K
84.73%-117K
61.53%-1.02M
---252K
--0
--0
---766K
---2.65M
--0
Cash from discontinued financing activities
Financing cash flow
--454K
2,021.60%5.3M
10.26%26.63M
-72.44%26.52M
4,146.00%2.12M
--0
-99.62%250K
--24.15M
-6.06%96.24M
--50K
Net cash flow
Beginning cash position
-55.88%56.27M
-55.21%74.14M
-66.33%65.22M
-16.84%193.73M
-61.28%89.96M
-45.37%127.55M
-17.42%165.52M
-16.84%193.73M
9.31%232.97M
-8.14%232.31M
Current changes in cash
57.74%-15.88M
52.94%-17.87M
131.63%8.92M
-227.46%-128.5M
35.89%-24.74M
-3,202.64%-37.58M
-215.02%-37.98M
13.31%-28.2M
-297.71%-39.24M
-93.49%-38.59M
End cash Position
-55.11%40.39M
-55.88%56.27M
-55.21%74.14M
-66.33%65.22M
-66.33%65.22M
-61.28%89.96M
-45.37%127.55M
-17.42%165.52M
-16.84%193.73M
-16.84%193.73M
Free cash flow
56.53%-16.34M
39.38%-23.17M
66.18%-17.71M
-14.43%-155.03M
30.48%-26.86M
-20.52%-37.58M
-15.41%-38.23M
-60.92%-52.35M
-64.02%-135.48M
-93.74%-38.64M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 56.53%-16.34M39.34%-23.17M66.18%-17.71M-14.53%-155.01M30.48%-26.86M-20.52%-37.58M-15.42%-38.21M-61.52%-52.35M-64.74%-135.34M-93.85%-38.64M
Net income from continuing operations 72.96%-13.65M84.49%-8.3M49.26%-26.79M-8.02%-179.05M59.39%-22.26M-20.76%-50.49M-42.06%-53.52M-67.76%-52.8M-55.01%-165.76M-109.79%-54.81M
Operating gains losses -481,900.00%-4.82M-2,104.40%-12.04M-112.99%-30K-206.08%-436K-125.74%-122K--1K---546K--231K793.48%411K--474K
Depreciation and amortization -2.53%77K-4.94%77K-2.50%78K-2.75%318K-3.70%78K-7.06%79K-3.57%81K3.90%80K10.10%327K6.58%81K
Other non cash items 75.49%1.51M73.83%1.45M66.54%1.33M82.30%3.53M4.11%1.04M38.87%861K--833K--801K--1.94M--997K
Change In working capital -116.65%-1.32M-161.48%-5.42M176.99%4.27M-80.60%2.02M-191.36%-9.2M44.60%7.95M2,855.31%8.82M-14.52%-5.55M108.90%10.4M159.47%10.07M
-Change in receivables 366.12%809K-193.24%-434K-777.14%-307K171.37%177K367.74%664K---304K---148K---35K---248K---248K
-Change in inventory 1,341.94%1.16M-992.59%-241K-1,457.58%-448K99.70%-6K104.68%27K-615.38%-93K103.79%27K104.84%33K---1.99M---577K
-Change in prepaid assets -164.82%-1.46M-131.03%-459K144.92%901K173.96%2.89M13.12%1.16M5.29%2.25M141.17%1.48M42.36%-2.01M-3,891.26%-3.91M-44.14%1.03M
-Change in payables and accrued expense -128.18%-1.74M-155.72%-4.2M221.55%4.21M-104.29%-722K-208.18%-10.97M82.88%6.17M88.87%7.54M-411.98%-3.46M247.09%16.83M396.48%10.14M
-Change in other current liabilities -8.64%-88K-10.13%-87K-7.79%-83K-8.87%-319K-9.33%-82K-9.46%-81K-8.22%-79K-8.45%-77K-23.63%-293K-8.70%-75K
Cash from discontinued investing activities
Operating cash flow 56.53%-16.34M39.34%-23.17M66.18%-17.71M-14.53%-155.01M30.48%-26.86M-20.52%-37.58M-15.42%-38.21M-61.52%-52.35M-64.74%-135.34M-93.85%-38.64M
Investing cash flow
Cash flow from continuing investing activities 085.61%-20K0068.76%-139K0
Net PPE purchase and sale --0--------85.61%-20K--0--0--------68.76%-139K--0
Cash from discontinued investing activities
Investing cash flow --0--0--085.61%-20K--0--0-5.26%-20K--068.76%-139K--0
Financing cash flow
Cash flow from continuing financing activities 454K2,021.60%5.3M10.26%26.63M-72.44%26.52M4,146.00%2.12M0-99.62%250K24.15M-6.06%96.24M50K
Net issuance payments of debt --------------0------------------98.6M--0
Net common stock issuance --468K--5.48M8.46%26.74M--27.03M--2.38M--0--0--24.66M--0--0
Proceeds from stock option exercised by employees --0--0--079.51%508K--0--035.14%250K--258K-80.54%283K--50K
Net other financing activities ---14K---172K84.73%-117K61.53%-1.02M---252K--0--0---766K---2.65M--0
Cash from discontinued financing activities
Financing cash flow --454K2,021.60%5.3M10.26%26.63M-72.44%26.52M4,146.00%2.12M--0-99.62%250K--24.15M-6.06%96.24M--50K
Net cash flow
Beginning cash position -55.88%56.27M-55.21%74.14M-66.33%65.22M-16.84%193.73M-61.28%89.96M-45.37%127.55M-17.42%165.52M-16.84%193.73M9.31%232.97M-8.14%232.31M
Current changes in cash 57.74%-15.88M52.94%-17.87M131.63%8.92M-227.46%-128.5M35.89%-24.74M-3,202.64%-37.58M-215.02%-37.98M13.31%-28.2M-297.71%-39.24M-93.49%-38.59M
End cash Position -55.11%40.39M-55.88%56.27M-55.21%74.14M-66.33%65.22M-66.33%65.22M-61.28%89.96M-45.37%127.55M-17.42%165.52M-16.84%193.73M-16.84%193.73M
Free cash flow 56.53%-16.34M39.38%-23.17M66.18%-17.71M-14.43%-155.03M30.48%-26.86M-20.52%-37.58M-15.41%-38.23M-60.92%-52.35M-64.02%-135.48M-93.74%-38.64M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.